Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.74 |
| ▸ | CTSC | P53634 | 3/20 | 0.69 |
| ▸ | CCNK | O75909 | 1/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | CCND3 | P30281 | 1/20 | 0.63 |
| ▸ | CDK9 | P50750 | 1/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526171 | 1.00 | BRD4 (1.00) | BRD4PKMYT1CTSCCCNKCCNA2 | |
| SCHEMBL17526321 | 0.90 | BRD4 (1.00) | BRD4CTSCCCNKCCND3CDK9 | |
| SCHEMBL11915885 | 0.84 | PKMYT1 (0.74) | BRD4PKMYT1CTSCCCNKCCNA2 | |
| SCHEMBL30306393 | 0.83 | BRD4 (1.00) | BRD4PKMYT1ALK | |
| SCHEMBL17526325 | 0.83 | BRD4 (1.00) | BRD4PKMYT1ALK | |
| SCHEMBL24842814 | 0.82 | CTSC (1.00) | BRD4CTSCALK | |
| SCHEMBL29816859 | 0.82 | CTSC (1.00) | BRD4CTSCALK | |
| SCHEMBL29816830 | 0.81 | CTSC (0.80) | BRD4CTSC | |
| SCHEMBL25658135 | 0.81 | CTSC (0.80) | BRD4CTSC | |
| SCHEMBL270416 | 0.80 | BRD4 (1.00) | BRD4CTSCALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | BRD4 1/4885PKMYT1 2856/4885CTSC 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.